MUMBAI, India — Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for metformin hydrochloride extended-release tablets USP, 500 mg and 1000 mg, the generic version of Glumetza Extended-Release Tablets, 500 mg and 1000 mg, of Salix Pharmaceuticals Inc. According to IQVIA sales data for the 12-month
MUMBAI, India — Glenmark has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for fulvestrant injection, 250 mg/5 mL (50 mg/mL), a generic version of Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP. According to IQVIATM sales data for the 12 month period ending June 2019,
MUMBAI, India — Glenmark Pharmaceuticals Inc. USA has received final approval from the Food and Drug Administration for lidocaine ointment 5%. Glemark said its product is a generic version of Xylocaine ointment 5% from AstraZeneca. A local anesthetic, lidocaine ointment is used for the treatment of pain or discomfort from skin irritations such as sunburn;
MUMBAI, India — Glenmark Pharmaceuticals Inc. USA has received final Food and Drug Administration approval for potassium chloride extended-release tablets. Glenmark said Wednesday that its potassium chloride ER tablets, which come in dosages of 10 mEq (750 mg) and 20 mEq (1500 mg), are a generic version of K-Dur ER tablets from Merck Sharp and
MUMBAI, India — Glenmark Pharmaceuticals Inc. USA has received final approval from the Food and Drug Administration for desmopressin acetate tablets in strengths of 0.1 mg and 0.2 mg. The company said Friday that the product, a generic equivalent of DDAVP (0.1 mg and 0.2 mg) from Ferring Pharmaceuticals Inc., has begun shipping. Desmopressin is
